Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics

NCT02291965 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT02291965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02291965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Observational
Overall status
Terminated
Start date
November 30, 2014
Completion date
October 7, 2024
Enrollment
139 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunodeficiency, leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome